Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sonnet BioTherapeutics Holdings, Inc.

Get SEC filing alerts via email and in your feed for Sonnet BioTherapeutics Holdings, Inc.

SONN

Sonnet BioTherapeutics Holdings, Inc.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is a clinical-stage biotechnology company developing innovative biologic medicines, primarily targeting oncology and neuropathy. Its proprietary F<sub>H</sub>AB platform enhances cytokine delivery and tumor targeting. The company’s pipeline includes cytokine-based therapies for cancer, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy, leveraging modular, long-acting constructs to improve efficacy and safety in immune modulation and nerve regeneration.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Sonnet BioTherapeutics Holdings, Inc.

1
1
Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Reports Fiscal Year 2025 Results and Completes Business Combination

Via official filing (AI summary) | 6 months ago | 0 comments

2
1
Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Reports $3.8 Million Net Loss in Q3 Fiscal 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Reports $3.5 Million Net Loss and Increased Collaboration Revenue in Latest Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Reports $1M Collaboration Revenue and $3.2M Net Loss for December 2024 Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments